PLMJ acts for GammaDelta on Lymphact acquisition
PLMJ advised UK-based GammaDelta Therapeutics on its acquisition of Portuguese company Lymphact – Lymphocyte Activation Technologies.
Lymphact is a biopharmaceutical start-up focused on the development of personalised medical treatments.
A GammaDelta Therapeutics statement said the acquisition would aid the “development of new immunotherapies aimed at treating a broad range of cancers, from haematological malignancies to solid tumours”.
Diogo Remechido Anjos, co-Founder and former chairman and CEO of Lymphact, said: “This transaction is a landmark for the Portuguese Biotech sector and I am confident GammaDelta Therapeutics is the right partner to help bring our DOT-Cells technology to patients. We are taking a decisive step in confirming the scientific innovation of biomedical research conducted in Portugal and also providing a clear signal the Portuguese entrepreneurial world is aware of such potential in the life sciences sector and is actually able to develop it.”
The PLMJ team included partners Barbara Godinho Correia and Manuel Lopes Rocha, as well as associates Pedro Gaspar da Silva and Lourenço Noronha dos Santos.
Lymphact was advised by CCA Ontier, whose team included managing partner Domingos Cruz, as well as associates Rita Trabulo and Rita Saias.